Custom Arrays


We are able to take discoveries made using our Immunome protein array and convert them into low-cost, highly multiplexed “custom” arrays. These can be formatted to run a very high number of samples in parallel but at a much lower cost, as only the signature that was discovered is used as content.

Custom arrays can also be made for new proteins from any species, however given the complexity and heterogeneity of each protein, each project requires significant time and resources to optimise expression and verify functionality.

ORVAR™ Selection Technology


Study Design:

  • Sample type:
    • Plasma from Colorectal cancer and healthy normal individuals
    • Tissue from Colorectal cancer individuals (cancer and adjacent normal tissue)
  • Platform:
    • Sengenics KREX CT100+ microarray
    • Orvar™ Autoproteome™ Discovery technology

Results:

Breakdown of Selected/Identified Antigens

Figure 1: Distribution and classification of the top antigens identified in both experiments



  • Non wild-type autoantigens – Positive results on Orvar™ only



  • Autoantigens unique to Orvar™ – Autoantigens not found on KREX microarray



  • Homologue autoantigens – Matched positive results between Orvar™ and KREX microarray



  • Wild-type autoantigens – Matched positive results between Orvar™ and KREX microarray

  • The Orvar™ technology identified a total of 28 unique autoantigens (Figure 2) which had corresponding autoantibodies present in Colorectal cancer patients;
  • This Orvar™ Colorectal library also led to the discovery of homologues to the antigens eliciting high autoantibody responses on KREX microarrays. These homologues may contain overlapping surface epitopes reactive to these autoantibodies;
  • As all antigens immobilised onto the KREX microarrays are present as wild-type forms, the unique antigens on Orvar™ which are also on KREX microarrays suggests detection of mutated forms of these antigens using the Orvar™ technology.

Figure 2: GO enrichment analysis for the top 28 unique autoantigens identified using Orvar™


FEATURED PRODUCTS

IMMUNOME Protein Array

High-throughput multiplexed autoantibody screening protein array containing 1600+
autoantigens

ImmuSAFE COVID Tests

Contains correctly folded antigens from SARS-CoV-2 and 25 other Corona and Influenza
viruses

SARS-CoV-2 Antigens

7 Recombinant SARS-CoV-2 antigens expressed using the patented KREX™ functional proteomics technology

Sengenics - Functional Proteomics | Krex Technology | Protein Array Supplier

Sengenics is a functional proteomics company that leverages its patented KREX technology for production of full-length, correctly folded and functional proteins. The key application of KREX is the discovery of autoantibody biomarkers for two core medical use cases:  stratification of patients undergoing treatment with autoimmune or cancer drugs and identification of autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Find Us On:

2008 – 2020© Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361 

X